Calibrating disease progression models using population data: a critical precursor to policy development in cancer control
- 7 June 2010
- journal article
- Published by Oxford University Press (OUP) in Biostatistics
- Vol. 11 (4), 707-719
- https://doi.org/10.1093/biostatistics/kxq036
Abstract
There are many more strategies for early detection of cancer than can be evaluated with randomized trials. Consequently, model-projected outcomes under different strategies can be useful for developing cancer control policy provided that the projections are representative of the population. To project population-representative disease progression outcomes and to demonstrate their value in assessing competing early detection strategies, we implement a model linking prostate-specific antigen (PSA) levels and prostate cancer progression and calibrate it to disease incidence in the US population. PSA growth is linear on the logarithmic scale with a higher slope after disease onset and with random effects on intercepts and slopes; parameters are estimated using data from the Prostate Cancer Prevention Trial. Disease onset, metastatic spread, and clinical detection are governed by hazard functions that depend on age or PSA levels; parameters are estimated by comparing projected incidence under observed screening and biopsy patterns with incidence observed in the Surveillance, Epidemiology, and End Results registries. We demonstrate implications of the model for policy development by projecting early detections, overdiagnosis, and mean lead times for PSA cutoffs 4.0 and 2.5 ng/mL and for screening ages 50-74 or 50-84. The calibrated model validates well, quantifies the tradeoffs involved across policies, and indicates that PSA screening with cutoff 4.0 ng/mL and screening ages 50-74 performs best in terms of overdiagnosis per early detection. The model produces representative outcomes for selected PSA screening policies and is shown to be useful for informing the development of sound cancer control policy.Keywords
This publication has 32 references indexed in Scilit:
- Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and ContextJNCI Journal of the National Cancer Institute, 2009
- Modeling Disease Progression With Longitudinal MarkersJournal of the American Statistical Association, 2008
- Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview SurveyCancer, 2007
- A population model of prostate cancer incidenceStatistics in Medicine, 2006
- LONG-TERM EFFECTS OF FINASTERIDE ON PROSTATE SPECIFIC ANTIGEN LEVELS: RESULTS FROM THE PROSTATE CANCER PREVENTION TRIALJournal of Urology, 2005
- PROSTATE BIOPSY FOLLOWING A POSITIVE SCREEN IN THE PROSTATE, LUNG, COLORECTAL AND OVARIAN CANCER SCREENING TRIALJournal of Urology, 2005
- Lead time associated with screening for prostate cancerInternational Journal of Cancer, 2003
- SERIAL PROSTATE SPECIFIC ANTIGEN, FREE-TO-TOTAL PROSTATE SPECIFIC ANTIGEN RATIO AND COMPLEXED PROSTATE SPECIFIC ANTIGEN FOR THE DIAGNOSIS OF PROSTATE CANCERJournal of Urology, 2001
- The percentage of free prostate specific antigen is an age-independent tumour marker for prostate cancer: establishment of reference ranges in a large populationBJU International, 1998
- Prostate-Specific Antigen as Predictor of Prostate Cancer in Black Men and White MenJNCI Journal of the National Cancer Institute, 1995